Dr. Reddy's Laboratories Limited

BSE:500124 Stock Report

Market Cap: ₹994.0b

Dr. Reddy's Laboratories Past Earnings Performance

Past criteria checks 2/6

Dr. Reddy's Laboratories has been growing earnings at an average annual rate of 27.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 12.1% per year. Dr. Reddy's Laboratories's return on equity is 17.5%, and it has net margins of 17.8%.

Key information

27.1%

Earnings growth rate

27.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate12.1%
Return on equity17.5%
Net Margin17.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Dr. Reddy's Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:500124 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24299,86753,33286,40225,906
30 Jun 24288,50755,57982,19024,082
31 Mar 24279,16455,68477,20122,873
31 Dec 23271,30252,20674,71721,362
30 Sep 23266,85450,88872,47020,618
30 Jun 23261,10947,21670,23520,040
31 Mar 23245,87945,06768,02619,381
31 Dec 22237,27936,35065,70818,341
30 Sep 22222,77630,94463,13817,679
30 Jun 22217,35129,73662,52917,273
31 Mar 22214,39123,56862,08117,482
31 Dec 21207,30726,31760,71717,250
30 Sep 21203,40619,45059,69317,199
30 Jun 21194,74117,15356,84917,095
31 Mar 21189,72217,23854,65016,541
31 Dec 20186,75621,25652,45716,637
30 Sep 20181,29815,36150,74016,478
30 Jun 20180,34018,66350,85015,781
31 Mar 20174,60019,49850,12915,410
31 Dec 19170,44816,20050,24614,882
30 Sep 19165,11026,74949,48414,601
30 Jun 19155,07920,86248,63915,059
31 Mar 19153,85118,79548,68015,607
31 Dec 18149,03417,47348,40016,293
30 Sep 18148,59415,96548,54017,292
30 Jun 18145,90313,77647,20017,347
31 Mar 18141,8559,80646,85718,265
31 Dec 17141,8279,90945,37018,458
30 Sep 17140,58811,26644,66318,747
30 Jun 17140,90711,36745,40519,786
31 Mar 17139,87012,03946,30019,513
31 Dec 16141,2699,66046,96119,718
30 Sep 16144,12710,75147,65918,857
30 Jun 16148,41015,01946,94318,116
31 Mar 16153,86620,01345,64117,701
31 Dec 15155,85024,45644,15218,100
30 Sep 15154,60224,40943,26418,321
30 Jun 15150,59222,93242,87917,961
31 Mar 15147,36022,17942,07617,329
31 Dec 14143,47421,80642,81016,289
30 Sep 14140,38022,24742,10214,952
30 Jun 14138,07623,40941,16513,847
31 Mar 14132,17021,51538,78312,402
31 Dec 13130,04322,40937,69510,852

Quality Earnings: 500124 has high quality earnings.

Growing Profit Margin: 500124's current net profit margins (17.8%) are lower than last year (19.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 500124's earnings have grown significantly by 27.1% per year over the past 5 years.

Accelerating Growth: 500124's earnings growth over the past year (4.8%) is below its 5-year average (27.1% per year).

Earnings vs Industry: 500124 earnings growth over the past year (4.8%) did not outperform the Pharmaceuticals industry 19.2%.


Return on Equity

High ROE: 500124's Return on Equity (17.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies